Bli medlem
Bli medlem

Du är här


Redeye: Redeye Initiates Coverage of Amniotics

Redeye initiates coverage of Amniotics, a Swedish biotech firm on the verge of first-mover advantage in the exciting field of off-the-shelf stem cell therapies. The four main disease areas it is targeting with allogeneic mesenchymal stem cells (MSCs) – uniquely derived from amniotic fluid – offer potential cost and clinical synergies for further indications. We believe the share is underfollowed and has considerable potential in the short as well as long run.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.


Redeye Initiates Coverage of Amniotics

Författare MFN

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.